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Objectives: Translational epidemiology studies often use archived tumor specimens to   evaluate 
genetic hypotheses involving cancer outcomes. When the exposure of interest is a germline 
polymorphism, a key concern is whether the genotype assayed from tumor-derived DNA is 
representative of the germline. We evaluated the concordance between breast tumor-derived 
and normal lymph node-derived genotypes for three polymorphic tamoxifen-metabolizing 
enzymes.
Methods: We assayed paired DNA samples extracted from archived tumor and normal lymph 
node tissues from 106 breast cancer patients. We used TaqMan assays to determine the geno-
types of three enzyme variants hypothesized to modify tamoxifen effectiveness, ie, CYP2D6*4, 
UGT2B15*2, and UGT1A8*2. We assessed genotype agreement between the two DNA sources 
by calculating the percent agreement and the weighted kappa statistic.
Results: We successfully obtained genotypes for CYP2D6*4, UGT2B15*2, and UGT1A8*2 in 
99%, 100%, and 84% of the paired samples, respectively. Genotype concordance was perfect 
for the CYP2D6*4 and UGT1A8*2 variants (weighted kappa for both = 1.00; 95% confidence 
interval [CI] 1.00, 1.00). For UGT2B15*2, one pair out of 106 gave a discordant result that 
persisted over several assay repeats.
Conclusions: We observed strong agreement between DNA from breast tumors and normal 
lymphatic tissue in the genotyping of polymorphisms in three tamoxifen-metabolizing enzymes. 
Genotyping DNA extracted from tumor tissue avoids the time-consuming practice of microdis-
secting adjacent normal tissue when other normal tissue sources are not available. Therefore, 
the demonstrated reliability of tumor-derived DNA allows resources to be spent instead on 
increasing sample size or the number of polymorphisms examined.
Keywords: molecular epidemiology, breast neoplasms, cytochrome P450 CYP2D6, 
glucuronosyltransferase
Introduction
Translational clinical epidemiology studies frequently use tissue archives as a resource 
for bioassays of cellular and molecular features, such as germline genotype or   protein 
expression in a tumor. The utility of archived tissues is tempered by inherent weak-
nesses of stored biologic material, for example, degradation of macromolecules over 
time, or the questionable representativeness of a tissue sample to a whole tumor 
or to a person.1–4 A specific example of the latter limitation is the use of archived 
breast tumors to assay germline genotypes of drug-metabolizing enzymes, which 
may modify the effectiveness of adjuvant therapies in terms of disease recurrence 
and survival.5 In such studies, it is uncommon to have available samples from more 
reliable sources of germline DNA, such as buccal cells or peripheral blood, and it is Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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therefore necessary to assume that a tumor-derived genotype 
is   representative of a patient’s germline.6,7 However, there is 
cause for   skepticism over this assumption, owing to a variety 
of potential DNA alterations in tumors that may interfere 
with accurate genotyping.2,3,8–10
Earlier studies have explored genotype concordance 
between reliable sources of germline DNA and breast tumor 
or tumor-adjacent tissue. Schneider et al compared genotype 
agreement for a panel of angiogenesis gene polymorphisms in 
17 breast tumor samples with paired lymph node samples.11 
Xie et al compared genotype agreement for five genes at 
loci with high rates of loss of heterozygosity in paired DNA 
samples from peripheral blood and microdissected breast 
tumor-adjacent normal tissue in 106 subjects.12 While both 
of these studies demonstrated 100% concordance between 
the different DNA sources, the use of tumor-adjacent   normal 
tissue by Xie et al and the small sample size enrolled by 
  Schneider et al leave open the question of whether DNA 
derived from formalin-fixed, paraffin-embedded (FFPE) 
breast tumor sections provides a reliable medium for the 
assay of germline genotype. Here we report the results from 
a large study of the concordance between genotypes of three 
tamoxifen-metabolizing enzymes assayed from archived 
FFPE breast carcinoma and normal lymph node tissues.
Materials and methods
study population
This study was approved by the Boston University Medical 
Campus Institutional Review Board and the Regional Com-
mittee on Biomedical Research Ethics of   Aarhus County, 
Denmark. We conducted the study among women aged 
35–70 years who were diagnosed with incident invasive 
breast carcinoma, ie, Union for International Cancer   Control 
(UICC) Stage I, II, or III, while living in one of seven 
counties in western Denmark between 1985 and 2001. The 
study sample was identified using the Danish Breast Cancer 
Cooperative Group registry to study associations between 
polymorphisms in genes encoding drug-metabolizing 
enzymes and tamoxifen resistance. Cases were defined as 
women with local or distant breast cancer recurrence. One 
recurrence-free control was incidence-density sampled and 
matched to each case for estrogen receptor expression, receipt 
of tamoxifen therapy, menopausal status at diagnosis (pre- or 
postmenopausal), date of breast cancer surgery (caliper-
matched ± 12 months), county of residence at diagnosis, and 
UICC stage at diagnosis (Stage I, II, or III). For each case 
and control, FFPE primary breast tumors were requested 
from the pathology departments at the admitting hospitals. 
Cancer-free FFPE lymph node tissue resected during primary 
surgical treatment was also requested for cases and controls 
when such tissue was available. For the present study, we 
aimed to enroll approximately 100 subjects for whom both 
tumor and normal tissues were received from pathology 
departments.
Tissue processing
Hematoxylin and eosin stained sections or written pathologic 
descriptions of the tumor and lymph node tissue blocks were 
reviewed by a pathologist to identify blocks for processing. 
Tissue blocks were processed in a laminar flow hood that 
had been sterilized with at least one hour of ultraviolet light 
exposure before use. Contaminating nucleases were removed 
by wiping all work surfaces and instruments with an aqueous 
solution of 1% (w/v) sodium dodecyl sulfate, followed by 
99.9% ethanol. Several sections were cut from each tissue 
block and discarded to ensure a clean starting surface for 
sample procurement. For DNA extractions, three to six 10 µm 
pieces were cut from each lymph node and tumor tissue block 
and placed in a 1.5 mL microtube. The cutting knife was 
wiped clean with the sodium dodecyl sulfate/ethanol series 
after each block, and the blade was replaced after every two 
blocks. Each blade was long enough to permit the cutting 
of two blocks without cross-contamination. Laboratory 
personnel changed gloves between blocks, and cut a pure 
paraffin control block after every 10 tissue blocks to serve 
as a contamination checkpoint.
DnA extraction
Before DNA extraction, all tissue samples were deparaf-
finized by treatment with xylene; 1 mL of xylene was added 
to each microtube containing three to six slices of paraffin-
embedded tissue and the microtubes were placed in a shak-
ing incubator at 45°C and 800 rpm for 20 minutes. Samples 
were then centrifuged at 12,200 rpm for five minutes, after 
which the supernatant was removed and discarded. The 
xylene treatment steps were repeated once for all samples. 
After deparaffinization, samples were incubated with 1 mL of 
99% ethanol in a shaking incubator at 60°C and 800 rpm for 
20 minutes, centrifuged at 12,200 rpm for five minutes, with 
subsequent removal of supernatant; ethanol treatment was 
repeated once for all samples. One drop of acetone was added 
to each tube, and tissue samples were evaporated to dryness 
at 60°C.   Tissues were then allowed to dissolve overnight in 
a shaking incubator at 55°C and 1000 rpm after addition of 
150 µL proteinase K (10 mg/mL) solution. The   following 
morning, proteinase K was inactivated by a 20-minute Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
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incubation at 98°C. DNA was then extracted from the tissue 
samples using a robotic magnet-assisted nucleic acid isolation 
instrument (MagnaPure, Roche Applied Science).
genotyping
From each tissue sample, 50 ng of extracted DNA were 
amplified in 25 µL polymerase chain reactions with 50 dena-
turation cycles at 92°C for 15 seconds, followed by annealing 
and extension at 60°C for 90 seconds, using primers and 
reagents supplied with TaqMan genotyping kits (Applied 
BioSystems, Foster City, CA). We compared normal lymph 
node tissue with tumor tissue on genotypes of three meta-
bolic enzyme single-nucleotide polymorphisms (SNPs), ie, 
cytochrome P450 2D6 (CYP2D6)*4 (rs3892097, ABI kit: 
C-27102431-D0); UDP-glucuronosyltransferase 2B15 
(UGT2B15)*2 (rs1902023, ABI kit: C-27028164-10); and 
UDP-glucuronosyltransferase 1A8 (UGT1A8)*2 (rs1042597, 
ABI kit: C-11742072-10). Additional data on these SNPs are 
shown in Table 1. These genes were selected for analysis 
because each plays a key role in the phase I (CYP2D6) or 
phase II (UGT2B15 and UGT1A8) metabolism of tamoxifen, 
and it is hypothesized that functional polymorphisms at these 
loci may modify the effectiveness of adjuvant tamoxifen 
therapy.5,13–17 All sample pairs were assayed in duplicate 
using the MX3000P real-time polymerase chain reaction 
system (Stratagene, Cedar Creek, TX). Positive controls for 
each variant were identified by sequencing peripheral blood 
DNA from 30 healthy individuals and included with each set 
of assays. Negative controls, with sterile water substituted 
for DNA, were also included in each run. Genotypes were 
classified as homozygous wild-type, homozygous variant, 
or heterozygous according to the autocall feature of the 
analytic software (MXPro QPCR version 4.1, Stratagene). 
If a sample failed to yield a called genotype it was reassayed 
using 70 ng of DNA in the amplification reaction. If the 
sample failed again, a new tissue section was cut from the 
paraffin block and the yield from the new DNA extraction 
was used for reassay. Samples that failed after re-extraction 
were excluded from the study.
statistical analysis
For all genes, we crosstabulated genotype frequencies accord-
ing to tissue type (normal lymph node and tumor) and calcu-
lated weighted kappa coefficients as a measure of   agreement 
between the two DNA sources.18 Because our kappa statistics 
were calculated from samples of modest size and were either 
approximately or exactly equal to unity, we calculated 95% 
confidence intervals (CI) around the point estimates by char-
acterizing the 2.5th and 97.5th percentiles of distributions 
of estimated kappas from 1000 bootstrapped samples of the 
original data.19 We also calculated percent agreement and 
corresponding mid-P 95% CI under a binomial distribution.20 
We calculated observed allele frequencies for each gene vari-
ant, based upon results from normal lymph node tissue, and 
compared these with benchmark values previously reported 
in European or Caucasian populations. We used observed and 
expected allele frequencies from normal lymph node tissue 
to calculate Chi-square statistics and test the null hypothesis 
that allele frequencies were in Hardy–Weinberg equilibrium. 
All statistical tests were two-sided, with a Type I error rate 
of 5%. All analyses were performed using SAS version 9.1 
(SAS Institute, Cary, NC).
Results
There were 106 paired normal lymph node and breast tumor 
tissue samples from the individual patients included in this 
study. The distribution of the paired samples   according 
to key clinical characteristics is reported in Table 2. 
Table 1 summary data for the snPs analyzed for tumor/normal tissue genotype concordance
Gene/variant Reference SNP Location Sequence [SNP] Expected allele  
frequencies 
Cytochrome P450 2D6/ CYP2D6*4 rs3892097 22q13.1 CCCCTTACCCgCATCTCCCACCCCCA  
[A/g] 
gACgCCCCTTTCgCCCCAACggTCT
A: 0.763 
g: 0.237a
UDP-glucuronosyltransferase 2B15/  
UGT2B15*2
rs1902023 4q13 TTTATCCTACATCTTTAACTAAAAAT 
[g/T] 
ATTTggAAgATTCTCTTCTgAAAAT
g: 0.560 
T: 0.440b
UDP-glucuronosyltransferase 1A8/ 
UGT1A8*2
rs1042597 2q37 CTCTgTggTCTTCgCCAggggAATAg  
[C/g] 
TTgCCACTATCTTgAAgAAggTgCA
C: 0.714 
g: 0.286a
Notes: aAllele frequencies reported for Caucasians on nCBi dbsnP database: http://www.ncbi.nlm.nih.gov/snp; bAllele frequencies reported for Europeans on ALFrED 
database: http://alfred.med.yale.edu21. 
Abbreviation: snP, single nucleotide polymorphism.Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
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Table  2  Distribution  of  106  tumor  and  normal  tissue  pairs 
according to demographic and clinical factors
Characteristic Paired tissue  
samples, n (%)
Patient age at diagnosis (y)
  35–44 8 (7.6)
  45–54 25 (24)
  55–64 42 (40)
  65–70 31 (29)
Year of diagnosis
  1985–1993 33 (31)
  1994–1996 36 (34)
  1997–2001 37 (35)
UiCC tumor stage at diagnosis
  stage i 2 (1.9)
  stage ii 60 (57)
  stage iii 44 (42)
Type of primary surgery
  Mastectomy 93 (88)
  Breast-conserving surgery 12 (11)
  Other 1 (0.9)
systemic adjuvant chemotherapya
  Yes 79 (75)
  no 27 (26)
radiation therapy
  Yes 63 (59)
  no 36 (34)
  Missing 7 (6.6)
Note: aDuring  the  study  period  chemotherapy  was  limited  to  the  adjuvant 
setting only. 
Abbreviation: UiCC, Union for international Cancer Control.
We successfully assayed CYP2D6*4 genotype in 105 
pairs (99%), UGT1A8*2 genotype in 89 pairs (84%), and 
UGT2B15*2 genotype in 106 pairs (100%). There was no 
difference between samples that genotyped successfully 
and those that failed to genotype successfully with regard to 
DNA purity (A260/A280 measurement), DNA concentration, 
length of amplified sequence, or age of the tissue block at 
the time of DNA extraction. Our main analyses are based 
on sample pairs with successfully assayed genotypes from 
both tissue sources.
Table 3 reports the crosstabulation of genotype frequen-
cies according to lymph node and tumor-derived DNA, the 
kappa statistic for agreement between the two tissue types, 
and results from Chi-square tests for   Hardy–Weinberg 
  equilibrium based on genotype frequencies from the   normal 
tissue samples. For all three genes, allele   frequencies observed 
in our study sample agreed with values reported in similar 
populations (Tables 1 and 3). Wild-type and variant allele 
frequencies for all three genes did not   deviate from Hardy–
Weinberg equilibrium (P $ 0.11 for all   Chi-square tests). 
Genotyping concordance was perfect for the CYP2D6*4 
and UGT1A8*2 variants (for both, weighted kappa = 1.00; 
95% CI 1.00, 1.00). Among the 106 pairs with a success-
fully assayed UGT2B15*2 genotype, one pair (0.9%) gave 
a discordant result. The normal lymph tissue indicated a 
homozygous variant genotype and the tumor   tissue indicated 
a homozygous wild-type genotype (weighted kappa = 0.97; 
95% CI 0.91, 1.00). This outcome was consistent across four 
repeated assays on the discordant pair, even after   re-extraction 
of DNA from the source   tissue blocks.
Discussion
Our study demonstrated high concordance between breast 
tumor- and normal lymph node-derived genotypes for 
key SNPs in drug-metabolizing enzymes, and agrees with 
observations from similar earlier studies. Previous work 
by Rae et al showed 100% concordance between CYP2D6 
genotypes from 10 FFPE archival breast tumors and matched 
peripheral blood samples.6 Schneider et al demonstrated 
100%   concordance between 17 breast tumor and lymph node 
samples for polymorphisms in two angiogenesis genes.11 
Xie et al reported 100% concordance for five genes from dif-
ferent high loss of heterozygosity sites in 106 paired samples 
of peripheral blood and microdissected normal tissue adjacent 
to breast tumor tissue.12 Our study provides evidence that 
breast tumor-derived genotypes are an acceptable proxy for 
germline genotypes when more suitable DNA sources are 
not available. This finding agrees with conclusions from 
two earlier reviews on this topic,21,22 and with results from 
other concordance studies using colorectal23 and non-small 
cell lung24 tumor DNA.
One of our target genes, CYP2D6, is located in a chromo-
somal region (22q13.1) that is commonly deleted in breast 
cancer cells.8 Thus, SNPs in CYP2D6 assayed from tumor-
derived DNA are at risk of misclassification due to loss of 
heterozygosity, yielding the expectation of imperfect geno-
type concordance between normal and tumor-derived DNA. 
The other SNPs lie in chromosomal regions that experience 
little or no deletion, so there is less expectation of imperfect 
concordance between normal and tumor-derived DNA 
for them. The perfect concordance we observed between 
CYP2D6 genotypes from the two different tissue types 
indicates either that loss of heterozygosity does not meaning-
fully distort CYP2D6 genotype classification in breast tumor 
cells, or that despite substantial loss of heterozygosity, tumor 
  sections contain sufficient stromal or adjacent normal tissue 
to report an accurate germline genotype. The perfect concor-
dance observed by Xie et al in five genes from high loss of 
heterozygosity sites also supports these notions, providing 
reassurance that loss of heterozygosity is not a major threat Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
245
Breast cancer genotype concordance
to genotype misclassification when breast tumor-derived 
DNA must be relied upon.
A limitation of our study is that our standard for germline 
genotype was DNA extracted from FFPE normal lymphatic 
tissue instead of from fresh nonmalignant tissue. Earlier 
work by Rae et al showed 100% genotype concordance 
between DNA from freshly harvested tumor cell cultures and 
DNA from tumor cell pellets that were formalin-fixed and 
embedded in paraffin before DNA extraction.6 Therefore, we 
consider our FFPE normal lymphatic tissue to be an accurate 
standard for the germline genotype that would be observed 
using fresh tissue.
In summary, we observed excellent agreement between 
archived breast tumor- and normal lymphatic tissue-derived 
DNA in classifying the germline genotype of three drug-
metabolizing enzyme variants (CYP2D6*4, UGT1A8*2, 
and UGT2B15*2) in sample sizes ranging from 89 to 106. 
Only one of the assayed gene variants (UGT2B15*2) gave 
a discrepant result, although in only one of 106 tested pairs. 
The discrepant result was a shift from homozygous wild-type 
in normal lymphatic tissue to a homozygous variant in the 
breast tumor tissue, in a chromosomal region not typically 
deleted in breast cancer.8 Therefore, while it is possible that 
the discrepancy arose from a tumor genome alteration, it 
is more plausible that a clerical error during either tissue 
archiving or processing resulted in the pairing of tumor and 
lymphatic tissues from separate patients.
Together, our observations indicate that FFPE archived 
breast tumors provide a reliable resource for the   determination 
of germline genotypes in CYP2D6, UGT2B15, UGT1A8, 
and likely other drug-metabolizing enzymes. It remains pos-
sible that mutations at other loci on the tumor genome could 
yield poorer concordance proportions than those observed 
for the three metabolic enzyme variants we studied. Our 
finding is important because genotyping DNA extracted 
from tumor tissue avoids the time-consuming practice 
of microdissection of adjacent normal tissue when other 
sources of normal tissue (eg, peripheral blood or lymph 
node) are not available. Study resources can then be devoted 
more cost-efficiently to, for example, increase sample size 
or genotyping capacity.
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Table 3 Cross tabulation of genotypes determined using DNA extracted from formalin-fixed, paraffin-embedded tumor and normal 
tissue from Danish breast cancer patients
Gene variant  
(Hardy–Weinberg  
P value)
Tumor tissue genotypes Normal tissue genotypes Concordance
wt/wt wt/var var/var Weighted κ  
(95% CI)
Agreement %   
(95% CI)
CYP2D6*4 (P = 0.46) wt/wt 66 0 0 1.00  
(1.00, 1.00)
100  
(97.2, 100) wt/var 0 36 0
var/var 0 0 3
normal tissue allele frequencies g: 0.80  
A: 0.20
UGT2B15*2 (P = 0.11) wt/wt 25 0 1 0.97  
(0.91, 1.00)
98.9  
(95.4, 99.1) wt/var 0 61 0
var/var 0 0 19
normal tissue allele frequencies g: 0.52  
T: 0.48
UGT1A8*2 (P = 0.22) wt/wt 47 0 0 1.00  
(1.00, 1.00)
100  
(96.7, 100) wt/var 0 32 0
var/var 0 0 10
normal tissue allele frequencies g: 0.71  
A: 0.29
Abbreviations: wt, wild-type; var, variant; CI, confidence interval.Clinical Epidemiology
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